Bcg Vaccine
Mostrando 1-12 de 213 artigos, teses e dissertações.
-
1. Cutaneous tuberculosis: epidemiological, clinical, diagnostic and therapeutic update
Abstract Tuberculosis is certainly one of the diseases considered to be ancient on planet Earth. The etiological agent of tuberculosis is Mycobacterium tuberculosis. This terrible bacterial infection still results in severe socioeconomic consequences to date, and its complete eradication represents a great challenge. It constitutes one of the most important
Anais Brasileiros de Dermatologia. Publicado em: 2022
-
2. IMMUNIZATION STATUS OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
RESUMO CONTEXTO: No tratamento de doenças inflamatórias intestinais (DII) são usados imunossupressores e agentes biológicos, o que aumenta o risco de infecções pela alteração da imunidade celular e humoral. A prevenção de algumas dessas infecções pode ser feita pela vacinação, entretanto pacientes com DII apresentam baixas taxas de cobertura
Arq. Gastroenterol.. Publicado em: 26/08/2019
-
3. Gain of function in Mycobacterium bovis BCG Moreau due to loss of a transcriptional repressor
The Bacille Calmette-Guérin (BCG) vaccine comprises a family of genetically different strains derived by the loss of genomic regions (RDs) and other mutations. In BCG Moreau, loss of RD16 inactivates rv3405c * , encoding a transcriptional repressor that negatively regulates the expression of Rv3406, an alkyl sulfatase. To evaluate the impact of this loss o
Mem. Inst. Oswaldo Cruz. Publicado em: 11/10/2018
-
4. Stable expression of Mycobacterium bovis antigen 85B in auxotrophic M. bovis bacillus Calmette-Guérin
BACKGROUND Bovine tuberculosis (TB) is a zoonotic disease caused by Mycobacterium bovis, responsible for causing major losses in livestock. A cost effective alternative to control the disease could be herd vaccination. The bacillus Calmette-Guérin (BCG) vaccine has a limited efficacy against bovine TB, but can improved by over-expression of protective ant
Mem. Inst. Oswaldo Cruz. Publicado em: 2017-02
-
5. The mc2-CMX vaccine induces an enhanced immune response against Mycobacterium tuberculosis compared to Bacillus Calmette-Guérin but with similar lung inflammatory effects
Although the attenuated Mycobacterium bovis Bacillus Calmette-Guérin (BCG) vaccine has been used since 1921, tuberculosis (TB) control still proceeds at a slow pace. The main reason is the variable efficacy of BCG protection against TB among adults, which ranges from 0-80%. Subsequently, the mc2-CMX vaccine was developed with promising results. Nonetheless,
Mem. Inst. Oswaldo Cruz. Publicado em: 2016-04
-
6. Risk-benefit assessment of Bacillus Calmette-Guérin vaccination, anti-phenolic glycolipid I serology, and Mitsuda test response: 10-year follow-up of household contacts of leprosy patients
Abstract: INTRODUCTION: Despite multidrug therapy, leprosy remains a public health issue. The intradermal Bacillus Calmette-Guérin (BCG) vaccine, Mitsuda test (lepromin skin test), and anti-phenolic glycolipid I (PGL-I) serology are widely used in leprosy studies and have shown great epidemiological value. METHODS: This longitudinal study evaluated the
Rev. Soc. Bras. Med. Trop.. Publicado em: 2015-12
-
7. Pattern of cytokine and chemokine production by THP-1 derived macrophages in response to live or heat-killed Mycobacterium bovis bacillus Calmette-Guérin Moreau strain
Tuberculosis has great public health impact with high rates of mortality and the only prophylactic measure for it is the Mycobacterium bovisbacillus Calmette-Guérin (BCG) vaccine. The present study evaluated the release of cytokines [interleukin (IL)-1, tumour necrosis factor and IL-6] and chemokines [macrophage inflammatory protein (MIP)-1α and MIP-1β] b
Mem. Inst. Oswaldo Cruz. Publicado em: 2015-09
-
8. Oral bacillus Calmette-Guérin vaccine against tuberculosis: why not?
The bacillus Calmette-Guérin (BCG) vaccine is the only licensed vaccine for human use against tuberculosis (TB). Although controversy exists about its efficacy, the BCG vaccine is able to protect newborns and children against disseminated forms of TB, but fails to protect adults against active forms of TB. In the last few years, interest in the mucosal deli
Mem. Inst. Oswaldo Cruz. Publicado em: 2014-09
-
9. Leprosy: a review of laboratory and therapeutic aspects - Part 2
Leprosy is a chronic infectious condition caused by Mycobacterium leprae(M. leprae). It is endemic in many regions of the world and a public health problem in Brazil. Additionally, it presents a wide spectrum of clinical manifestations, which are dependent on the interaction between M. leprae and host, and are related to the degree of immunity to the bacillu
An. Bras. Dermatol.. Publicado em: 2014-06
-
10. Leprosy exposure, infection and disease: a 25-year surveillance study of leprosy patient contacts
Contact surveillance is a valuable strategy for controlling leprosy. A dynamic cohort study of leprosy contacts was initiated in 1987 at Oswaldo Cruz Foundation. The objective of this work was to review the data on the major risk factors leading up to the infectious stage of the disease, estimate incidence rates of leprosy in the cohort and characterise the
Mem. Inst. Oswaldo Cruz. Publicado em: 2012-12
-
11. Rational design of diagnostic and vaccination strategies for tuberculosis
The development of diagnostic tests which can readily differentiate between vaccinated and tuberculosis-infected individuals is crucial for the wider utilization of bacillus Calmette-Guérin (BCG) as vaccine in humans and animals. BCG_0092 is an antigen that elicits specific delayed type hypersensitivity reactions similar in size and morphological aspects to
Brazilian Journal of Infectious Diseases. Publicado em: 2012-02
-
12. INQUÉRITO DOMICILIAR SOBRE A COBERTURA VACINAL DO ESQUEMA BÁSICO ATÉ O SEGUNDO ANO DE VIDA, SÃO LUIS, MARANHÃO / HOUSEHOLD SURVEY ON THE COVER VACCINE SCHEDULE OF BASIC TO THE SECOND YEAR LIFE, SÃO LUÍS, MARANHÃO
A vacinação das crianças no primeiro ano de vida é fundamental para a prevenção de várias doenças transmissíveis e é um dos fatores associados à redução da taxa de mortalidade infantil. A identificação da cobertura vacinal e dos fatores responsáveis pelo retardo ou pela falta de imunização é fundamental para a adequada monitorização dos
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 07/10/2011